Benefits
Acute stem cell mobilization (Drapeau 2019) — preliminary
Drapeau, Benson, Jensen 2019 (PMID 30787601, PMC6368418, NCT03388073, Clinical Interventions in Aging 14:253-263) — small (n=12) randomized double-blind placebo-controlled crossover. 500 mg sea buckthorn proanthocyanidin extract; blood samples at 1 and 2 hours. CD45dim CD34+ CD309- progenitor stem cells increased significantly vs baseline at 2h (p<0.007), but vs placebo did NOT reach significance (p<0.17). Industry-funded (Biomx Stemceuticals). Hypothesis-generating only.
Antioxidant capacity (ORAC and cellular)
ORAC value claims position CyanthOx™ as 8× grape seed extract and 1.7× pine bark extract. ORAC is a chemical antioxidant assay — strong correlate of polyphenol content but NOT a validated clinical outcome marker (FDA dropped ORAC database in 2012 due to misuse in marketing). Cellular studies (CyanthOx™80 in RAW 264.7 macrophages) show protection against H₂O₂-induced oxidative damage. Mechanism plausible; clinical translation to specific outcomes not established.
Prodelphinidin chemistry — distinguishing feature
Most plant proanthocyanidin extracts (grape seed, pine bark) are predominantly PROCYANIDINS — built from catechin/epicatechin units. CyanthOx™ is predominantly PRODELPHINIDINS — built from gallocatechin/epigallocatechin units, with an additional hydroxyl group. This structural difference may produce different bioavailability and bioactivity profiles vs procyanidin-based extracts. Clinical implications of this difference are not yet definitively established by head-to-head trials.
Cardiovascular and skin claims — mechanism-level
Manufacturer markets cardiovascular, skin, and circulation support based on antioxidant mechanism plus extrapolation from broader sea buckthorn and proanthocyanidin literature. No dedicated CyanthOx™ RCTs for cardiovascular or skin endpoints have been published in peer-reviewed journals as of 2026. Generic sea buckthorn evidence (vitamin C, omega-7 oils) is distinct from this proanthocyanidin extract evidence. Honest framing: marketing claims outpace dedicated branded clinical evidence.
Sea buckthorn whole-plant context
CyanthOx™ is a polyphenol-fraction extract specifically — distinct from sea buckthorn berry oil (omega-7 palmitoleic acid) or sea buckthorn juice (vitamin C). Each fraction has different bioactives and clinical evidence profile. For mucous membrane hydration, dry eye, and Sjögren's: omega-7 sea buckthorn oil has stronger evidence. For polyphenol-mediated antioxidant claims: CyanthOx™ is the relevant fraction but evidence is still preliminary.
Tibetan Plateau sourcing claim
Marketing emphasizes sea buckthorn grown on the Tibetan Plateau as having superior bioactive content due to high-altitude UV exposure and environmental stress. This terroir-style claim has some plausibility — UV exposure can increase plant secondary metabolite production. Specific quantitative comparisons of Tibetan vs other-origin sea buckthorn proanthocyanidin content not independently published. Source verification depends on supply chain transparency.
Generally well-tolerated
Sea buckthorn has long history of food and traditional medicine use. CyanthOx™ at 500 mg in the Drapeau 2019 trial was well-tolerated with no reported adverse events. Long-term safety data specifically for the concentrated proanthocyanidin extract is limited but the parent food has good safety profile. Pregnancy/lactation: limited specific safety data for the concentrated extract.
Mechanism of action
Prodelphinidin antioxidant activity
Prodelphinidins are built from gallocatechin/epigallocatechin units — structurally distinct from procyanidins (catechin/epicatechin). The additional hydroxyl group on the B-ring may give different free radical scavenging kinetics and metal-chelation profile. ORAC values position the extract as more potent than common procyanidin sources, though chemical assays don't perfectly predict clinical effects.
Bioflavonoid contribution
Sea buckthorn berries also contain quercetin, kaempferol, and isorhamnetin glycosides. These bioflavonoids have independent antioxidant and anti-inflammatory activity. Likely contribute to overall extract effects beyond proanthocyanidin alone.
Possible stem cell mobilization signal
Drapeau 2019 showed acute increase in CD45dim CD34+ CD309- progenitor stem cells 2 hours post-dose vs baseline (significant) but not vs placebo (not significant). Mechanism for any such effect would involve polyphenol-mediated signaling on bone marrow stem cell egress. Effect would need replication in larger trials before being considered established.
Polyphenol bioavailability considerations
Like other proanthocyanidin extracts, polymerization affects absorption — monomers and oligomers absorb better than polymeric forms. Specific bioavailability of CyanthOx™ prodelphinidins vs other extract types not fully characterized. Consumed with food generally improves polyphenol absorption.
Clinical trials
Randomized double-blind placebo-controlled crossover trial in 12 healthy subjects (mean age 49.3 years, 8 female/4 male). Single 500 mg dose of sea buckthorn proanthocyanidin extract vs placebo. Blood draws at baseline, 1 hour, and 2 hours post-dose. Significant increase in CD45dim CD34+ CD309- progenitor stem cells at 2 hours vs baseline (p<0.007). Comparison to placebo did NOT reach statistical significance (p<0.17). Industry-funded (Biomx Stemceuticals). Hypothesis-generating; needs replication.
Cited industry comparison: CyanthOx™ shows 1.7× ORAC capacity vs French maritime pine bark extract. 8× ORAC vs grape seed extract per Superfoodly.com analysis. Important context: ORAC is a chemical assay, not a clinical outcome. FDA discontinued ORAC database in 2012 due to misuse in marketing claims that didn't translate to clinical benefit. Strong polyphenol content suggested but clinical relevance requires outcome trials.
In vitro studies in RAW 264.7 macrophage cells. CyanthOx™80 at 25, 50, 100 μg/mL provided protection against H₂O₂-induced oxidative damage (800 μmol/L for 4 hours). Cellular mechanism support for antioxidant claims. Not human clinical evidence — limited clinical translation extrapolation appropriate.